Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.
about
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.Correlation between Virus Replication and Antibody Responses in Macaques following Infection with Pandemic Influenza A Virus.An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.Influence of prior influenza vaccination on antibody and B-cell responses.Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract.Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine.An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infectionSublingual vaccination with influenza virus protects mice against lethal viral infection.Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccinesSystemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccinesSubclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virusComparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human influenza A virus reassortants derived from different avian influenza virus donors.In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memoryEvaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccineRecombinant immunoglobulin A specific for influenza A virus hemagglutinin: production, functional analysis, and formation of secretory immunoglobulin A.Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.Health-seeking behavior and transmission dynamics in the control of influenza infection among different age groups.
P2860
Q30374887-B8F0818B-A471-4556-B6D4-B62778424E6EQ30377443-ED8D9935-96D7-443C-BA87-DA068B6A4AF2Q30378263-A364A63D-9C81-49C7-ABEB-BAEF00D03376Q30381056-97DC8333-84E5-498E-86F5-8039A078ABBDQ30414282-86F88F53-FAB1-4ACC-AF12-8C015461CCDAQ33361605-39210C5F-C712-4DF5-B955-9B7DD1A51A6FQ33592225-B20F9FF9-4AF3-4444-956C-A5819C5470FFQ33676505-B461F875-4DB9-4C21-B57B-E1194E403616Q33834576-4DCB40C0-EAE8-4103-A478-FD925F2575A4Q33852342-3C54AD2B-B5FE-4936-BC7A-16821E03E10DQ34003245-09FF8DA6-3359-4E9D-A0F7-0EAE6AA65178Q34006839-316C7B73-131D-4EB5-B8A0-DF6AB2729EB4Q34730017-B4584A10-8DDD-4CA7-96F5-D664789E9A04Q35017702-83E28629-8704-4B25-A15B-F2B56BCB7398Q36250143-8F9477B0-FF8A-4F1B-87BC-585884E21C10Q36446440-16C6B4C1-8227-46D5-9E75-F30EC96753AAQ37149005-C3E01012-2919-4925-857F-CA6D5975AFDCQ37163516-BB4712EB-4E2E-4940-ADE0-0147479030CEQ37196156-AF90D2A1-48D9-44E6-8984-944594DE201BQ37199623-CCACA860-7A4D-4E35-9DE1-EDC416799EFAQ37200967-91E1FE47-556A-4ECD-B10A-A48FDAF06004Q37204545-8F1F1502-BCE7-4975-929E-651F5CD3098DQ37207762-B6D2F22D-94F6-4F86-BBE9-64E070F7D9C3Q37209873-2CF3974D-F967-4694-90DA-4B1F8649AABBQ37231712-124911B2-5BB3-4CE0-B3CC-F6351BD9A6E5Q37235698-A78CDBF9-FDEE-47C6-95C8-FD4C2A345426Q37282506-619F9AC2-13B0-4338-9666-F96D0106D6B1Q39396092-A53077AF-0637-4F0B-866E-3FF36A5CCA5FQ39642529-16288177-4015-4C45-90A0-0B15C5F98CEEQ51783228-7F0BF1CD-2209-41B9-BE5C-A97134EE70B1
P2860
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@ast
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@en
type
label
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@ast
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@en
prefLabel
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@ast
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@en
P2093
P2860
P1476
Dose response of A/Alaska/6/77 ...... infection with vaccine virus.
@en
P2093
B R Murphy
M L Clements
M M Levine
R M Chanock
S O'Donnell
P2860
P304
P407
P577
1983-06-01T00:00:00Z